The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback